+ T Cells
Mice (n = 4–6 for each group) bearing large TC-1 tumors, were treated in one of four ways: 1) No treatment (Control); 2) I.P. α-CCL2 mAb (a-CCL2); 3) S.Q. vaccine with Ad.E7 (Ad.E7); and 4) combination of Ad.E7 and α-CCL2. Two days after the second (booster) Ad.E7 vaccine, tumors were harvested.
Panels A–B summarize the number of intratumoral CD8+ cells by IHC (Panel A), and their percentage of total tumor by flow cytometry (Panel B). The combination of vaccine plus CCL2/CCL12 blockade significantly increased intra-tumoral CD8+ cells (*=p<0.05). Each dot represents one mouse.
Panel C summarizes the percentage of intratumoral CD8+ T cells expressing the activation marker 4-1BB, showing increased activity in the combination therapy (*=p<0.05).
Panel D summarizes the percentage of intratumoral CD8+/tetramer-E7+ cells, showing increased antigen-specific cells in the combination therapy (*=p<0.05).